MARKET

PCVX

PCVX

Vaxcyte, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.00
+1.47
+2.91%
After Hours: 52.00 0 0.00% 16:00 09/25 EDT
OPEN
50.29
PREV CLOSE
50.53
HIGH
53.94
LOW
50.17
VOLUME
223.37K
TURNOVER
--
52 WEEK HIGH
58.48
52 WEEK LOW
17.80
MARKET CAP
2.43B
P/E (TTM)
-275.1323
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 3d ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 4d ago
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
\- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -\- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions -MENLO PARK, Calif. and GREENWICH
GlobeNewswire · 4d ago
How To Avoid The Noise And Invest For Long-Term Success
Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging.Avoiding noise and executing under pressure are critical to investing success.I've been managing custom-built equity portfolios since 2012, and hope to engage with those on Seeking Alpha interested in long-term investment success.I will look to do this with the tools I've developed to manage portfolios.
Seekingalpha · 6d ago
We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/14 19:27
Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference
FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide
GlobeNewswire · 09/09 22:28
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 20)
Benzinga · 08/21 11:43
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 12:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCVX. Analyze the recent business situations of Vaxcyte, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCVX stock price target is 49.50 with a high estimate of 55.00 and a low estimate of 44.00.
EPS
Institutional Holdings
Institutions: 38
Institutional Holdings: 36.20M
% Owned: 77.42%
Shares Outstanding: 46.76M
TypeInstitutionsShares
Increased
0
0
New
38
36.20M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
Kurt von Emster
President/Chief Executive Officer/Co-Founder/Director
Grant Pickering
Co-Founder/Vice President
Jeff Fairman
Co-Founder
Ashish Khanna
Chief Financial Officer/Primary Contact
Elaine Sun
Director
Patrick Enright
Director
Peter Hirth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PCVX
Vaxcyte, Inc. is a vaccine company. The Company is developing vaccines to prevent some common and deadly infectious diseases. The Company’s cell-free protein synthesis platform enables to design and produce protein carriers and antigens, the critical building blocks of vaccines. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV). The Company’s lead vaccine candidate is, VAX-24, is a 24-valent investigational PCV. The Company’s candidate include VAX-XP, leverages scalable and modular platform and builds on the technical concept established by VAX-24; VAX-A1 for Group A Strep and VAX-PG for periodontitis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Vaxcyte Inc stock information, including NASDAQ:PCVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCVX stock methods without spending real money on the virtual paper trading platform.